Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

Osteoporosis International

Volumn 21, Issue 6, 2010, Pages 1021-1029

  Abelson, A ^a   Ringe, J D ^b   Gold, D T ^c   Lange, J L ^d   Thomas, T ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c DUKE UNIVERSITY   (United States)

^d PROCTER AND GAMBLE COMPANY   (United States)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Bisphosphonates; Clinical fractures; Effectiveness; Epidemiology; Osteoporosis

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

AGE FACTORS; AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; EPIDEMIOLOGIC METHODS; ETIDRONIC ACID; FEMALE; HIP FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; UNITED STATES;

EID: 77954559281     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1046-3     Document Type: Article

References (49)

1. Avorn J (2007) In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med 357:2219-2221
2. Perreault S, Dragomir A, Blais L et al (2008) Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture. Pharmacoepidemiol Drug Saf 17:248-259
3. Langsetmo LA, Morin S, Richards JB et al (2009) Effectiveness of antiresorptives for the prevention of nonvertebral low-trauma fractures in a population-based cohort of women. Osteoporos Int 20:283-290
4. Morin S, Rahme E, Behlouli H et al (2007) Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos Int 18:1625-1632
5. Feldstein AC, Weycker D, Nichols GA et al (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153-159
6. Blouin J, Dragomir A, Moride Y et al (2008) Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol 66:117-127
7. Curtis JR, Westfall AO, Cheng H et al (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101, 038 new bisphosphonate users. J Bone Miner Res 23:1435-1441
8. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511-517
9. Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569-1575
10. Meijer WM, Beest FJ, Olson M, Herings RM (2008) Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Curr Med Res Opin 24:3217-3222
11. Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811-818
12. Sunyecz JA, Mucha L, Baser O et al (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 19:1421-1429
13. Curtis JR, Westfall AO, Cheng H et al (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613-1620
14. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287
15. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
16. van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE et al (2006) Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 22:1757-1764
17. Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
18. Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271-277
19. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
20. Silverman SL, Watts NB, Delmas PD et al (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25-34
21. Cadarette SM, Katz JN, Brookhart MA et al (2008) Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148:637-646
22. Curtis JR, Westfall AO, Cheng H et al (2009) Risedronat E and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int 20 (6):973-978
23. Harris ST, Reginster JY, Harley C et al (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 44 (5):758-765
24. Mauri L, Silbaugh TS, Garg P et al (2008) Drug-eluting or baremetal stents for acute myocardial infarction. N Engl J Med 359:1330-1342
25. Jackson LA, Jackson ML, Nelson JC et al (2006) Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35:337-344
26. Bonnick S, Saag KG, Kiel DP et al (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91:2631-2637
27. Harrington JT, Ste-Marie LG, Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129-135
28. Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124
29. Melton LJ 3rd, Thamer M, Ray NF et al (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16-23
30. American College Of Rheumatology Ad Hoc Committee On Glucocorticoid- Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496-1503
31. Riggs BL, Melton LJ 3rd, Robb RA et al (2006) Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age-and sex-specific patterns of hip and wrist fractures. J Bone Miner Res 21:315-323
32. Johnell O, Kanis JA, Odén A et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175-179
33. Brookhart MA, Avorn J, Katz JN et al (2007) Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 120:251-256
34. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
35. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915-920
36. D'Agostino RB Jr, D'Agostino RB Sr (2007) Estimating treatment effects using observational data. JAMA 297:314-316
37. Shapiro S (2000) Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 151:939-945
38. Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-397
39. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
40. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082
41. Liberman UA, Weiss SR, Bröll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
42. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344-1352
43. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
44. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
45. Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
46. MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197-213
47. Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237-245
48. McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811-817
49. Ray WA, Griffin MR, Fought RL, Adams ML (1992) Identification of fractures from computerized Medicare files. J Clin Epidemiol 45:703-714